CRP and cancer: This lower response to sunitinib in patients with higher serum CRP levels may be attributed to an aggressive disease status, reflected by higher CRP levels, the acquisition of resistance to therapeutic agents through an increase in inflammatory mediators in the cancer-cell microenvironment, or compromised drug metabolism induced by such mediators associated with CRP [21].